---
document_datetime: 2025-11-23 07:05:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva.html
document_name: imatinib-teva.html
version: success
processing_time: 0.130319
conversion_datetime: 2025-12-28 10:49:17.039112
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imatinib Teva

[RSS](/en/individual-human-medicine.xml/65949)

##### Authorised

This medicine is authorised for use in the European Union

imatinib

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Imatinib Teva](#more-information-on-imatinib-teva-1155)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Imatinib Teva. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Imatinib Teva.

For practical information about using Imatinib Teva, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Imatinib Teva and what is it used for?

Imatinib Teva is a cancer medicine. It is used to treat the following diseases:

- chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control. Imatinib Teva is used when the patients are 'Philadelphia chromosome positive' (Ph+). This means that some of their genes have re?arranged themselves to form a special chromosome called the Philadelphia chromosome. Imatinib Teva is used in adults and children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant. It is also used in adults and children in the 'chronic phase' of the disease if it is not responding to interferon alpha (another cancer medicine), and in more advanced phases of the disease ('accelerated phase' and 'blast crisis');
- Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly. Imatinib Teva is used in combination with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL. It is also used alone in adults to treat Ph+ ALL that has returned following previous treatment, or is not responding to other medicines;
- myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells. Imatinib Teva is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
- advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control. Imatinib Teva is used to treat adults with HES or CEL who have a specific re?arrangement of two genes called FIP1L1 and PDGFR?;
- dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably. Imatinib Teva is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.

Imatinib Teva contains the active substance imatinib. It is a 'generic medicine'. This means that Imatinib Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Glivec.

## How is Imatinib Teva used?

Imatinib Teva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood. It is available as capsules (100 and 400 mg) and tablets (100 and 400 mg) and is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut. The dose depends on the age and condition of the patient, and the response to treatment, but it should not exceed 800 mg a day. For more information, see the package leaflet.

## How does Imatinib Teva work?

The active substance in Imatinib Teva, imatinib, is a protein-tyrosine kinase inhibitor. This means that it blocks some specific enzymes known as tyrosine kinases. These enzymes can be found in certain receptors in cancer cells, including the receptors that are involved in stimulating the cells to divide uncontrollably. By blocking these receptors, Imatinib Teva helps to control cell division.

## How has Imatinib Teva been studied?

Because Imatinib Teva is a generic medicine, studies in patients have been limited to tests to determine that the tablets and capsules are bioequivalent to the reference medicine, Glivec. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Imatinib Teva?

Because Imatinib Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Imatinib Teva approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Imatinib Teva has been shown to have comparable quality and to be bioequivalent to Glivec. Therefore, the CHMP's view was that, as for Glivec, the benefit outweighs the identified risk. The Committee recommended that Imatinib Teva be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Imatinib Teva?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imatinib Teva have been included in the summary of product characteristics and the package leaflet.

## Other information about Imatinib Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Imatinib Teva on 8 January 2013. For more information about treatment with Imatinib Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Imatinib Teva : EPAR - Summary for the public

Reference Number: EMA/772979/2012

English (EN) (89.56 KB - PDF)

**First published:** 17/01/2013

**Last updated:** 22/11/2016

[View](/en/documents/overview/imatinib-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-631)

български (BG) (110.34 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/bg/documents/overview/imatinib-teva-epar-summary-public_bg.pdf)

español (ES) (92.42 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/es/documents/overview/imatinib-teva-epar-summary-public_es.pdf)

čeština (CS) (106.1 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/cs/documents/overview/imatinib-teva-epar-summary-public_cs.pdf)

dansk (DA) (88.7 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/da/documents/overview/imatinib-teva-epar-summary-public_da.pdf)

Deutsch (DE) (88.94 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/de/documents/overview/imatinib-teva-epar-summary-public_de.pdf)

eesti keel (ET) (89.91 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/et/documents/overview/imatinib-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (110.48 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/el/documents/overview/imatinib-teva-epar-summary-public_el.pdf)

français (FR) (92.69 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/fr/documents/overview/imatinib-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (101.52 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/hr/documents/overview/imatinib-teva-epar-summary-public_hr.pdf)

italiano (IT) (87.33 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/it/documents/overview/imatinib-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (103.87 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/lv/documents/overview/imatinib-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (104.01 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/lt/documents/overview/imatinib-teva-epar-summary-public_lt.pdf)

magyar (HU) (101.82 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/hu/documents/overview/imatinib-teva-epar-summary-public_hu.pdf)

Malti (MT) (107.43 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/mt/documents/overview/imatinib-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (91.71 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/nl/documents/overview/imatinib-teva-epar-summary-public_nl.pdf)

polski (PL) (107.54 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/pl/documents/overview/imatinib-teva-epar-summary-public_pl.pdf)

português (PT) (89.07 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/pt/documents/overview/imatinib-teva-epar-summary-public_pt.pdf)

română (RO) (102.88 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/ro/documents/overview/imatinib-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (105.43 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/sk/documents/overview/imatinib-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (98.83 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/sl/documents/overview/imatinib-teva-epar-summary-public_sl.pdf)

Suomi (FI) (88.8 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/fi/documents/overview/imatinib-teva-epar-summary-public_fi.pdf)

svenska (SV) (86.84 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

22/11/2016

[View](/sv/documents/overview/imatinib-teva-epar-summary-public_sv.pdf)

## Product information

Imatinib Teva : EPAR - Product Information

English (EN) (1.59 MB - PDF)

**First published:** 17/01/2013

**Last updated:** 01/10/2024

[View](/en/documents/product-information/imatinib-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-618)

български (BG) (2.17 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/bg/documents/product-information/imatinib-teva-epar-product-information_bg.pdf)

español (ES) (1.66 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/es/documents/product-information/imatinib-teva-epar-product-information_es.pdf)

čeština (CS) (2.11 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/cs/documents/product-information/imatinib-teva-epar-product-information_cs.pdf)

dansk (DA) (1.59 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/da/documents/product-information/imatinib-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.72 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/de/documents/product-information/imatinib-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.59 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/et/documents/product-information/imatinib-teva-epar-product-information_et.pdf)

ελληνικά (EL) (1.8 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/el/documents/product-information/imatinib-teva-epar-product-information_el.pdf)

français (FR) (2 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/fr/documents/product-information/imatinib-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.69 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/hr/documents/product-information/imatinib-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.57 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/is/documents/product-information/imatinib-teva-epar-product-information_is.pdf)

italiano (IT) (1.93 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/it/documents/product-information/imatinib-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.85 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/lv/documents/product-information/imatinib-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.02 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/lt/documents/product-information/imatinib-teva-epar-product-information_lt.pdf)

magyar (HU) (1.81 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/hu/documents/product-information/imatinib-teva-epar-product-information_hu.pdf)

Malti (MT) (1.92 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/mt/documents/product-information/imatinib-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.58 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/nl/documents/product-information/imatinib-teva-epar-product-information_nl.pdf)

norsk (NO) (1.78 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/no/documents/product-information/imatinib-teva-epar-product-information_no.pdf)

polski (PL) (2.11 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/pl/documents/product-information/imatinib-teva-epar-product-information_pl.pdf)

português (PT) (1.59 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/pt/documents/product-information/imatinib-teva-epar-product-information_pt.pdf)

română (RO) (1.74 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/ro/documents/product-information/imatinib-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.8 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/sk/documents/product-information/imatinib-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.69 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/sl/documents/product-information/imatinib-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.63 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/fi/documents/product-information/imatinib-teva-epar-product-information_fi.pdf)

svenska (SV) (1.65 MB - PDF)

**First published:**

17/01/2013

**Last updated:**

01/10/2024

[View](/sv/documents/product-information/imatinib-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0056 30/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imatinib Teva : EPAR - All Authorised presentations

English (EN) (16.26 KB - PDF)

**First published:** 17/01/2013

**Last updated:** 14/07/2016

[View](/en/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-415)

български (BG) (51.58 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/bg/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.96 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/es/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.26 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/cs/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.17 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/da/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.82 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/de/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.76 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/et/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.9 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/el/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (14.86 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/fr/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.25 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/hr/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.71 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/is/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.51 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/it/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (48.7 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/lv/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.89 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/lt/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.9 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/hu/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (46.42 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/mt/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.39 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/nl/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.2 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/no/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (46.99 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/pl/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.16 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/pt/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.35 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/ro/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.22 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/sk/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (28.51 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/sl/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.38 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/fi/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.12 KB - PDF)

**First published:**

17/01/2013

**Last updated:**

14/07/2016

[View](/sv/documents/all-authorised-presentations/imatinib-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imatinib Teva Active substance imatinib International non-proprietary name (INN) or common name imatinib Therapeutic area (MeSH)

- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Myelodysplastic-Myeloproliferative Diseases
- Hypereosinophilic Syndrome
- Dermatofibrosarcoma

Anatomical therapeutic chemical (ATC) code L01EA01

### Pharmacotherapeutic group

- Antineoplastic agents
- Protein kinase inhibitors

### Therapeutic indication

Imatinib Teva is indicated for the treatment of

- Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr?abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
- Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon?alpha therapy, or in accelerated phase or blast crisis.
- Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
- Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
- Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
- Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

Imatinib Teva is indicated for

- the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
- the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
- The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

## Authorisation details

EMA product number EMEA/H/C/002585

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 18/10/2012 Marketing authorisation issued 07/01/2013 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imatinib Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (163.88 KB - PDF)

**First published:** 24/06/2013

**Last updated:** 01/10/2024

[View](/en/documents/procedural-steps-after/imatinib-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Imatinib Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/593709/2012

English (EN) (185.63 KB - PDF)

**First published:** 17/01/2013

**Last updated:** 17/01/2013

[View](/en/documents/assessment-report/imatinib-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imatinib Teva

Adopted

Reference Number: EMA/CHMP/597641/2012

English (EN) (62.16 KB - PDF)

**First published:** 19/10/2012

**Last updated:** 19/10/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-teva_en.pdf)

#### More information on Imatinib Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/10/2024

## Share this page

[Back to top](#main-content)